SCHEMBL2735481

SCHEMBL2735481

CC(C)C(=O)OCC(O)COC(=O)C(C)C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.35
KDM4E B2RXH2 2/20 0.35
DUSP3 P51452 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ADRB2 P07550 4/20 0.35
ADRB1 P08588 4/20 0.35
ADRB3 P13945 4/20 0.35
CYP1A2 P05177 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 2/20 0.34
LPAR6 P43657 1/20 0.34
LPAR1 Q92633 1/20 0.34
LPAR4 Q99677 1/20 0.34
LPAR5 Q9H1C0 1/20 0.34
LPAR2 Q9HBW0 1/20 0.34
LPAR3 Q9UBY5 1/20 0.34
ENPP2 Q13822 1/20 0.34
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12156887 0.91 ADRB2 (0.32) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL13168070 0.91 KDM4E (0.35) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL15249360 0.91 TDP1 (0.45) LMNAKDM4EMEN1KMT2ACYP1A2
SCHEMBL3635596 0.87 LMNA (0.48) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL12762794 0.87 KDM4E (0.36) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL25491976 0.87 KMT2A (0.33) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL14540316 0.87 TSHR (0.36) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL22710480 0.87 KDM4E (0.41) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL13168180 0.87 KDM4E (0.33) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL13168158 0.85 KDM4E (0.32) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174534-A1 COMPOUNDS USEFUL IN HIV THERAPY GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2023-06-08 US disclosed
EP-4010349-A1 4'-ETHYNYL-2'-DEOXYADENOSINE DERIVATIVES AND THEIR USE IN HIV THERAPY GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) 2022-06-15 EP disclosed
US-8088546-B2 Underlayer coating forming composition for lithography containing naphthalene ring having halogen atom NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-01-03 US disclosed
US-20070238029-A1 Underlayer Coating Forming Composition for Lithography Containing Naphthalene Ring Having Halogen Atom NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-10-11 US disclosed
US-5225590-A Alkoxy methyl ether and alkoxy methyl ester derivatives SYNTEX (U.S.A.) INC. (US) 1993-07-06 US disclosed
EP-0187297-B1 ALKOXY METHYL ETHER AND ALKOXY METHYL ESTER DERIVATIVES SYNTEX (U.S.A.) INC. (US) 1991-08-21 EP disclosed
EP-0187297-A2 Alkoxy methyl ether and alkoxy methyl ester derivatives SYNTEX (U.S.A.) INC. (US) 1986-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174534-A1 COMPOUNDS USEFUL IN HIV THERAPY CCR5, CD4, LSS LMNA 2608/4885KDM4E 3040/4885DUSP3 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.